DrugCard

Local literature screening for pharmaceutical companies.

DrugCard Overview

What is DrugCard?

DrugCard is an AI-enabled tool that specializes in local literature screening for the pharmaceutical industry. It is designed to streamline drug safety routines and ensure compliance with regulatory requirements. The tool offers continuous and regular screening, allowing pharmaceutical companies to stay up-to-date with the latest literature in their local markets. It provides traceability and transparency, allowing users to track the screening process and ensuring that it is accurate, complete, and holistic.DrugCard is scalable to new markets, making it suitable for companies looking to expand their operations globally. It supports multiple languages and suppliers, allowing for a comprehensive screening process.One key advantage of DrugCard is that it does not require heavy capital investments, making it a cost-effective solution for pharmaceutical companies. The platform supports over 100 languages and covers medical journals from over 35 countries, providing extensive coverage for screening. It boasts a high accuracy rate in scanned PDF screening.DrugCard caters to different users within the pharmaceutical industry, including Contract Research Organizations (CROs), Marketing Authorization Holders (MAHs), and freelancers. It enables CROs to manage more projects and improve screening results, while MAHs can choose to perform in-house screening to mitigate compliance and reputation risks. Freelancers can also benefit from the tool by saving time on literature screening and focusing on other value-adding activities.Overall, DrugCard offers a reliable and efficient solution for local literature screening, providing the pharmaceutical industry with the necessary tools to streamline drug safety processes and meet regulatory requirements. Help other people by letting them know if this AI was useful. Add your own prompts and outputs to help others understand how to use this AI.

Screenshot gallery

A Professional Framework to Evaluate DrugCard

When considering DrugCard for integration into your organizational workflow, we recommend deploying a structured score card across three critical operational pillars: Security & Compliance, Integration Friction, and long-term Price Scalability. Rather than looking only at basic feature lists, modern procurement teams must assess how a software platform behaves under high load and how well it fits into the team's data security guidelines.

1. Security and Database Compliance

Depending on your operating region and field, ensure that DrugCard supports standard security layers such as SOC 2 Type II certifications, GDPR compliance, or HIPAA-compliant database encryption. If the tool connects directly to client database tables or handles user passwords, verify that they implement multi-factor authentication (MFA), single sign-on (SSO) integrations, and end-to-end data encryption in transit and at rest.

2. API Coverage and Custom Integrations

Siloed data is the primary cause of operational friction. Evaluate if DrugCard has native connectors for your current project trackers, messaging hubs, and customer communication channels. For custom developer requirements, check if they provide a fully documented REST API with reasonable rate limits, comprehensive Webhooks support, and robust SDK packages in your language. A flexible API layer saves hundreds of hours of manual copy-paste overhead.

3. Total Cost of Ownership (TCO)

SaaS pricing packages are often deceptively simple. When reviewing DrugCard's billing structure, map out your team's projected expansion over the next 12 to 24 months. Determine how costs scale as your customer database increases or as you add team members. Factor in setup costs, mandatory support plan upgrades, API access fees, and storage overage rates to understand the true cost before committing to a contract.

By combining verified user reviews from our directory with internal workflow pilot tests, your procurement team can make an informed decision that drives productivity without creating capital waste.